Ligand-based pharmacophore modeling and Bayesian approaches to identify c-Src inhibitors

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 29, Issue 1, 2014, Pages 69-80

  Sakkiah, Sugunadevi ^a   Arullaperumal, Venkatesh ^a   Hwang, Swan ^a   Lee, Keun Woo ^a  

^a Gyeongsang National University   (South Korea)

Author keywords

Bayesian theory; C Src; HypoGen; LigandFit; Molecular docking; Pharmacophore

Indexed keywords

ASPARTIC ACID; GLUTAMIC ACID; LIGAND; METHIONINE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE;

ARTICLE; BAYES THEOREM; CRYSTAL STRUCTURE; DATA BASE; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME INHIBITION; HYDROGEN BOND; IC 50; MOLECULAR DOCKING; MOLECULAR INTERACTION; PHARMACOPHORE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; VALIDATION STUDY;

BAYES THEOREM; LIGANDS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PROTO-ONCOGENE PROTEINS PP60(C-SRC);

EID: 84893488518     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756366.2012.753881     Document Type: Article

References (44)

1. Cohen P. Protein kinases-The major drug targets of the twenty-first century. Nat Rev Drug Discov 2002;1:309-15
2. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65
3. Michael Bradshaw J. The Src, Syk, and Tec family kinases: Distinct types of molecular switches. Cell Signal 2010;22:1175-84
4. Sadowski I, Stone JC, Pawson T. A noncatalytic domain conserved among cytoplasmic protein-Tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps. Mol Cell Biol 1986;6:4396-408
5. Mayer BJ, Hamaguchi M, Hanafusa H. A novel viral oncogene with structural similarity to phospholipase C. Nature 1988;332:272-5
6. Xu W, Harrison SC, Eck MJ. Three-dimensional structure of the tyrosine kinase c-Src. Nature 1997;385:595-602
7. Banibrata S, Faye MJ. Regulation of Src family kinases in human cancers. J Signal Transduct 2011;2011:1-14
8. Pan Q, Qiao F, Gao C, et al. Cdk5 targets active Src for ubiquitindependent degradation by phosphorylating Src (S75). Cell Mol Life Sci 2011;68:3425-36
9. Sicheri F, Moarefi I, Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 1997;385:602-9
10. Martin GS. The hunting of the Src. Nat Rev Mol Cell Biol 2001;2:467-75
11. Margaret CF. Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta Rev Cancer 2002;1602:114-30
12. Courtneidge SA. Role of Src in signal transduction pathways. Biochem Soc Trans 2002;30:11-17
13. Kraker AJ, Hartl BG, Amar AM, et al. Biochemical and cellular effects of c-Src kinase-selective pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharm 2000;60:885-98
14. Blake RA, Broome MA, Liu X, et al. SU6656, a selective Src family kinase inhibitor, used to probe growth factor signaling. Mol Cel Biol 2000;20:9018-27
15. Wang YD, Miller K, Boschelli DH, et al. Inhibitors of Src tyrosine kinase: The preparation and structure-Activity relationship of 4-Anilino-3-cyanoquinolines and 4-Anilinoquinazolines. Bio Med Chem Lett 2000;10:2477-80
16. Berger D, Dutia M, Powell D, et al. Substituted 4-Anilino-7-phenyl-3- quinolinecarbonitriles as Src kinase inhibitors. Bio Med Chem Lett 2002;12:2989-92
17. Boschelli DH, Wang DY, Ye F, et al. Inhibition of Src kinase activity by 4-Anilino-7-Thienyl-3-quinolinecarbonitriles. Bioorg Med Chem Lett 2002;12:2011-14
18. MacKerell AD, Brooks CL, Nilsson L, et al. CHARMM: The energy function and its parameterization with an overview of the program. In: Schleyer PVR, ed. The encyclopedia of computational chemistry, Vol. 1. Chichester: John Wiley & Sons; 1998:271-7
19. Brooks B, Bruccoleri R, Olafson B, et al. CHARMM: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 1983;4:187-217
20. Sakkiah S, Thangapandian S, John S, et al. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. Eur J Med Chem 2010;45:2132-40
21. Sakkiah S, Baek A, LeeKW. Pharmacophore modeling and molecular dynamics simulation to identify the critical chemical features against human sirtuin2 inhibitors. J Mol Stru 2012;1011:66-75
22. Debnath AK. Generation of predictive pharmacophore models for CCR5 antagonists: Study with piperidine-And piperazine-based compounds as a new class of HIV-1 entry inhibitors. J Med Chem 2003;46:4501-15
23. Lu IL, Tsai KC, Chiang YK, et al. A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors. Eur J Med Chem 2008;43:1603-11
24. National Cancer Institute. 2004. Available from: Http://cactus.nci.-nih. gov/download/nci [last accessed 31 Jan 2013
25. Maybridge Chemical Company Ltd. Maybridge Chemical Database. Available from: Http://www.maybridge.com
26. Chembridge. Available from: Http://chembridge.com
27. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26
28. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
29. Venkatachalam CM, Jiang X, Oldfield T, Waldman M. LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model 2003;21:289-307
30. Sakkiah S, Thangapandian S, John S, Lee KW. Identification of critical chemical features for Aurora kinase-B inhibitors using Hip-Hop, virtual screening and molecular docking. J Mol Struct 2011;985:14-26
31. Dalgarno D, Stehle T, Narula S, et al. Structural basis of src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds. Chem Biol Drug Des 2006;67:46-57
32. Gehlhaar DK, Verkhivker GM, Rejto PA, et al. Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming. Chem Biol 1995;2:317-24
33. Muegge I. PMF scoring revisited. J Med Chem 2005;49:5895-902
34. Jain AN. Scoring noncovalent protein-ligand interactions: A continuous differentiable function tuned to compute binding affinities. J Comput Aided Mol Des 1996;10:427-40
35. Krammer A, Kirchhoff PD, Jiang X, et al. LigScore: A novel scoring function for predicting binding affinities. J Mol Graph Model 2005;23:395-407
36. Böhm HJ. The computer program LUDI: A new method for the de novo design of enzyme inhibitors. J Comput Aided Mol Des 1992;6:61-78
37. Friesner RA, Banks JL, Murphy RB, et al. Glide: A new approach for rapid, accurate docking and scoring. 1: Method and assessment of docking accuracy. J Med Chem 2004;47:1739-49
38. Glick M, Jenkins JL, Nettles JH, et al. Enrichment of highthroughput screening data with increasing levels of noise using support vector machines, recursive partitioning, and Laplacianmodified naive Bayesian classifiers. J Chem Inf Model 2005;46:193-200
39. Gelman A, Carlin JB, Stern HS. Bayesian model analysis. 3rd ed. London: Chapman & Hall; 2003
40. Thangapandian S, John S, Sakkiah S, Lee KW. Pharmacophorebased virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors. Eur J Med Chem 2011;46:1593-603
41. Oberdoerffer P, Michan S, McVay M., et al. SIRT1 Redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 2008;135:907-18
42. Imai Si, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000;403:795-800
43. Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. Nucleic Acids Res 2011;39:W270-7
44. Triballeau N, Acher F, Brabet I, et al. Virtual screening workflow development guided by the ''Receiver Operating Characteristic'' curve approach. Application to high-Throughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 2005;48:2534-47